Adjuvant nivolumab may be promising for treatment of completely resected Merkel cell carcinoma
1. Disease-free survival at 24 months was 84% in the nivolumab group compared to 73% in the observation group. 2. ...
Tag: skin cancer
The Scan by 2 Minute Medicine®: Millions off Medicaid, Hugh Jackman’s Skin Cancer Scare, Artemis II Crew, Earth Day
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. ...
#StudyGraphics: Atezolizumab in combination with vemurafenib and cobimetinib improve progression-free survival in patients with BRAFV600-advanced melanoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Neoadjuvant–Adjuvant vs. Adjuvant-Only Pembrolizumab in Advanced Melanoma
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the adjuvant-only group (72% vs 49%). 2. ...
#VisualAbstract: Adjuvant pembrolizumab improves distant metastasis-free survival in stage IIB-C melanoma
Click to read this study in The Lancet Oncology.
#VisualAbstract: Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
The Scan by 2 Minute Medicine®: World Mental Health Day, Beneath the Band-aid, Trouble in Uganda and Carbon Monoxide Leak Sickens Dozens!
The Scan by 2 Minute Medicine® is a new pop-culture medical newsletter designed to bring a physician perspective to trending ...
Nivolumab plus ipilimumab improves recurrence-free survival in patients with resected advanced melanoma
1. 4-year recurrence-free survival was significantly higher with nivolumab plus ipilimumab compared to placebo. 2. Overall survival was significantly higher ...
Stereotactic body radiation does not improve outcomes in patients with advanced Merkel cell carcinoma receiving nivolumab and ipilimumab
1. Objective response rate was not significantly different in patients treated with stereotactic body radiotherapy compared to those without. 2. ...
#VisualAbstract: Combination of spartalizumab plus dabrafenib and trametinib does not significantly improve survival in BRAFV600-mutated metastatic melanoma
Click to read this study in the Journal of Clinical Oncology.
License Our Award-Winning Physician-Written Medical News and Visual Abstracts
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
